Talecris Biotherapeutics Study Demonstrates Aerosolized Prolastin(R) Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs

Published: Sep 18, 2007

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. (http://www.talecris.com) presented new data today at the 2007 Annual Congress of the European Respiratory Society (ERS) demonstrating that using the AKITA2® APIXNEB® system (Activaero Technologies) to inhale Prolastin® (Alpha-1 Proteinase Inhibitor [Human]) results in very high levels of drug deposited in the central and peripheral regions of the lungs. The clinical study data demonstrated that distribution in patients with alpha-1 antitrypsin (AAT) deficiency and cystic fibrosis who had moderate to severe lung function impairment was similar to levels achieved in healthy subjects.

Back to news